NCT06345794

A Study to Assess LY4100511 (DC-853) in Healthy Adult Participants

A Phase 1, Single-Center, Open-Label, 3-Cohort, Fixed-Sequence, Drug-Drug Interaction Study To Assess The Pharmacokinetics Of LY4100511 (DC-853) When Orally Administered Alone, When Coadministered With Itraconazole, Fluconazole, Or Carbamazepine In Healthy Adult Participants

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 50 (actual)
• Sponsor: DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The main purpose of this study is to assess the effect of multiple doses of itraconazole, fluconazole, and carbamazepine on single dose pharmacokinetic of LY4100511 (DICE-853) in healthy participants. The study will also evaluate the safety and tolerability of LY4100511 (DICE-853) with itraconazole, fluconazole, and carbamazepine.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	LY4100511 (DC-853)	Administered orally.
DRUG	Itraconazole	Administered orally.
DRUG	Fluconazole	Administered orally.
DRUG	Carbamazepine	Administered orally.

Timeline

• Start date: 2024-04-03
• Primary completion: 2024-06-18
• Completion: 2024-06-18
• First posted: 2024-04-03
• Last updated: 2025-04-27

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study